SBIR/STTR Research Award

Minimally-Invasive Image-Guided Therapy for Cancer Treatment

Award identifier d604854c68681287d102f5fc5188689049b0443c07c33ab733578da336e8458cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$149,562

Program and phase

STTR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CONTRADYN, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The long-term objective of this research is to develop a technology and eventually a minimally-invasive commercial system for image-guided photodynamic therapy for cancer. This is certainly in keeping with NCI's focus o n imaging in vivo for cancer screening, diagnosis, progression, image-guide therapy, treatment monitoring, and recurrence. In studies conducted at the University of Utah's Department of Pharmaceutics, Professor Lu's research team has designed and synthesiz ed a bifunctional polymer containing an MRI contrast agent and a photosensitizer, and has demonstrated strong visualization of mouse tumors in MRI with the bifunctional conjugate, and good therapeutic efficacy when tumors were treated photodynamic therapy. ContraDyn, Inc. has licensed the technology which has allowed for this advance. Thus this proposal is a collaborative effort among the University of Utah, the inventor, and ContraDyn, Inc. Building on Professor Lu's work this proposal will incorporate a s pecific targeting agent to reduce the amount of chemicals to which people would be exposed. Challenges still to be met for photodynamic therapy include delivery of sufficient photosensitizer to target tissues, and accurate light-irradiation of the target. An efficient targeted drug-delivery system for both the photosensitizer and imaging probe is the ultimate goal of this program. Specifically, this grant would allow us to 1) design, synthesize, and characterize a tumor-specific targeted, bifunctional polym er; 2) evaluate the efficacy of the targeted, bifunctional polymer for tumor imaging and cancer treatment in a tumor-mouse model at several doses; and 3) optimize the synthesis and analytical methods for the safest formulation of the targeted, bifunctional polymer. PUBLIC HEALTH RELEVANCE: Photodynamic therapy has been shown to be an effective approach for treating cancers which are not accessible to surgery or are resistant to chemotherapy. Currently with photodynamic therapy it is difficult to remove, abl ate, or treat tumor-tissue without harming the surrounding normal tissue. Addition of tumor-targeting agents and improved delivery systems should result in better outcomes and reduced damage to surrounding tissues.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.